| Company Name: | Martek Biosciences Corporation | | Ticker Symbol: | MATK | | | WWW Address: | www.martek.com | | CEO: | Steve Dubin | | No. of Employees: | 569 | | Common Issue Type: | CS | | Business Description: | The Company is engaged in the innovation and development of omega-3 DHA products that promote health and wellness through every stage of life and a provider of omega-6 ARA to the infant formula industry.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 18.09 |  0.0 | 15.1 | 18.42 | 18.0 | 18.18 | 17.91 | 157015 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 601.3 | 33.2 | 0.97 | 1.13 | 0.00 | 15.1 | 0.0 | 31.35 - 15.36 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 18.09 | $ | | PE Ratio - LTM | 15.1 | |
| Market Capitalisation | 601.3 | mil |
| Latest Shares Outstanding | 33.2 | mil |
| Earnings pS (EPS) | 1.13 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 619,265 | $ |
| Effective Tax Rate | 34.3 | % |
| Float | 32.7 | mil |
| Float as % of Shares Outstanding | 98.4 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 15.00 | % |
| Research & Devlopment (R&D) as % of Revenue | 7.90 | % |
| Gross Profit Margin | 48.6 | % |
| EBITDA Margin | 25.7 | % |
| Pre-Tax Profit Margin | 17.5 | % |
| Assets Turnover | 0.5 | % |
| Return on Assets (ROA) | 5.9 | % |
| Return on Equity (ROE) | 6.4 | % |
| Return on Capital Invested (ROCI) | 6.4 | % |
| Current Ratio | 7.1 | |
| Leverage Ratio (Assets/Equity) | 1.1 | |
| Interest Cover | 162.4 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 8.36 | $ |
| Cash pS | 3.89 | $ |
| Book-Value pS | 18.76 | $ |
| Tangible Book-Value pS | 16.24 | $ |
| Cash Flow pS | 2.06 | $ |
| Free Cash Flow pS | 2.01 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.96 | |
| Price/Tangible Book Ratio | 1.11 | |
| Price/Cash Flow | 8.8 | |
| Price/Free Cash Flow | 9.0 | |
| P/E as % of Industry Group | 66.0 | % |
| P/E as % of Sector Segment | 11.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Dividend Declared Date | 09/21/2008 |
| Dividend Ex-Date | 09/25/2008 |
| Dividend Record Date | 09/29/2008 |
| Dividend Pay Date | 10/09/2008 |
| Dividend Amount | 1 |
| Type of Payment | Cash Payment |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -0.1 | 98 | 2,760 | 5,753 |
| 4 Weeks | 19.45 | 17.15 | 17.96 | 0.7 | 94 | 2,657 | 47,817 |
| 13 Weeks | 25.42 | 17.15 | 24.89 | -27.3 | 67 | 3,100 | 192,200 |
| 26 Weeks | 25.43 | 17.15 | 21.19 | -14.6 | 71 | 3,264 | 411,288 |
| 52 Weeks | 31.35 | 15.36 | 27.95 | -35.3 | 52 | 3,820 | 955,019 |
| YTD | 31.35 | 15.36 | - | -40.3 | 49 | 3,833 | 873,813 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 17.93 | 18.15 | 20.10 | 21.44 | 20.64 | 0.97 | 0.91 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 15.09 | 95.1 | 9.46 |
| Income | 5.99 | 5.8 | 25.56 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -32.71 | NA | -37.26 |
| R&D | 10.07 | NA | 5.19 |
| Normalized Inc. | 4.75 | NA | 19.07 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -1.7 | -12.0 | 14.8 |
| Earnings % | -12.0 | -4.3 | 17.7 |
| EPS % | 8.5 | -3.6 | 15.3 |
| EPS $ | 0.07 | -0.01 | 0.15 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 34.80 |
| Current Ratio | 5.7 |
| Quick Ratio (Acid Test) | 3.0 |
| Liquidity Ratio (Cash) | 2.16 |
| Receivables Turnover | 8.6 |
| Average Collection Period | 42 |
| Working Capital/Equity | 38.2 |
| Working Capital pS | 6.95 |
| Cash-Flow pS | 2.05 |
| Free Cash-Flow pS | 2.87 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 7.58 |
| Financial Leverage Ratio (Assets/Equity) | 1.1 |
| Debt Ratio | 8.9 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 1.7 |
| LT Debt/Total Liabilities | 1.4 |
| Interest Cover | 113.4 |
| Interest/Capital Invested | 0.09 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 0.47 |
| Tobin's Q Ratio | 0.93 |
| Current P/E Ratio - LTM | 15.10 |
| Enterprise Value (EV)/EBITDA | 6.56 |
| Enterprise Value (EV)/Free Cash Flow | 9.17 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 1.11 |
| Price/Book Ratio - LTM | 0.96 |
| Price/Cash Flow Ratio | 8.8 |
| Price/Free Cash Flow Ratio - LTM | 9.0 |
| Price/Sales Ratio | 1.73 |
| P/E Ratio (1 month ago) - LTM | 15.9 |
| P/E Ratio (26 weeks ago) - LTM | 18.3 |
| P/E Ratio (52 weeks ago) - LTM | 20.3 |
| 5-Y High P/E Ratio | 146.9 |
| 5-Y Low P/E Ratio | 19.9 |
| 5-Y Average P/E Ratio | 39.1 |
| Current P/E Ratio as % of 5-Y Average P/E | 39 |
| P/E as % of Industry Group | 66.0 |
| P/E as % of Sector Segment | 11.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 15.1 |
| PER SHARE FIGURES |
| LT Debt pS | 0.02 |
| Current Liabilities pS | 1.46 |
| Tangible Book Value pS - LTM | 16.24 |
| Book Value pS - LTM | 18.76 |
| Capital Invested pS | 17.73 |
| Cash pS - LTM | 3.89 |
| Cash Flow pS - LTM | 2.06 |
| Free Cash Flow pS - LTM | 2.01 |
| Earnings pS (EPS) | 1.13 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 26.36 |
| Free Cash Flow Margin 5YEAR AVG | -17.41 |
| Net Profit Margin | 10.7 |
| Net Profit Margin - 5YEAR AVRG. | 11.2 |
| Equity Productivity | 0.60 |
| Return on Equity (ROE) | 6.4 |
| Return on Equity (ROE) - 5YEAR AVRG. | 6.2 |
| Capital Invested Productivity | 0.60 |
| Return on Capital Invested (ROCI) | 6.4 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 5.7 |
| Assets Productivity | 0.60 |
| Return on Assets (ROA) | 5.8 |
| Return on Assets (ROA) - 5YEAR AVRG. | 5.1 |
| Gross Profit Margin | 48.6 |
| Gross Profit Margin - 5YEAR AVRG. | 44.9 |
| EBITDA Margin - LTM | 25.7 |
| EBIT Margin - LTM | 17.6 |
| Pre-Tax Profit Margin | 16.3 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 12.4 |
| Effective Tax Rate | 34.3 |
| Effective Tax Rate - 5YEAR AVRG. | -0.5 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 244 |
| Revenue per Employee | 619,265 |
| Net Income per Employee | 66,199 |
| Average Collection Period | 41 |
| Receivables Turnover | 8.6 |
| Day's Inventory Turnover Ratio | 203 |
| Inventory Turnover | 1.8 |
| Inventory/Sales | 28.3 |
| Accounts Payble/Sales | 4.85 |
| Assets/Revenue | 1.67 |
| Net Working Capital Turnover | 1.57 |
| Fixed Assets Turnover | 0.94 |
| Total Assets Turnover | 0.6 |
| Revenue per $ Cash | 3.44 |
| Revenue per $ Plant | 1.33 |
| Revenue per $ Common Equity | 0.60 |
| Revenue per $ Capital Invested | 0.60 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 15.8 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 16.2 |
| Research & Devlopment (R&D) as % of Revenue | 7.4 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 7.4 |
|
|  
|
| |
 |  |